BioNTech SE (BNTX) Net Margin (2018 - 2026)
BioNTech SE (BNTX) posted Net Margin of 16.51% for Q4 2025, down 421.06% sequentially from 5.14% in Q3 2025, and down 1652.0% YoY from 1.06% in Q4 2024.
Powered by 
Analysis
BioNTech SE (BNTX) Net Margin (2018 - 2026) Analysis & Trends
BioNTech SE has reported Net Margin for 8 years, with the latest figure at 16.51% in Q4 2025.
- Quarterly Net Margin fell 1652.0% year-over-year to 16.51% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 31.84% (down 3182.0% YoY) and the FY2025 annual result came in at 39.59%, down 1540.0% from the prior year.
- Net Margin fell to 16.51% in Q4 2025 per BNTX's latest filing, from 5.14% in the prior quarter.
- Over five years, Net Margin peaked at 105.28% in Q1 2021 and troughed at 624.55% in Q2 2024.
- A 5-year average of 38.28% and a median of 21.22% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2025: Net Margin slumped 47086 bps in 2023, then surged 46397 bps in 2025.
- Over 5 years, Net Margin stood at 0.0% in 2021, then soared by 166085745 bps to 95.05% in 2022, then slumped by 38 bps to 58.72% in 2023, then slumped by 100 bps to 0.01% in 2024, then plunged by 158976 bps to 16.51% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 16.51%, 5.14%, and 160.58% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | -849.05% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -849.05% |
| Mar 31, 2026 | -418.80% |
| Dec 31, 2025 | -16.51% |
| Sep 30, 2025 | 5.14% |
| Jun 30, 2025 | -160.58% |
| Mar 31, 2025 | -235.67% |
| Dec 31, 2024 | 28.82% |
| Sep 30, 2024 | 9.58% |
| Jun 30, 2024 | -83.61% |
| Mar 31, 2024 | 11.89% |
| Dec 31, 2023 | 58.72% |
| Sep 30, 2023 | -0.96% |
| Jun 30, 2023 | 4.89% |
| Mar 31, 2023 | -0.03% |
| Dec 31, 2022 | 95.05% |
| Sep 30, 2022 | 0.31% |
| Jun 30, 2022 | 92.81% |
| Mar 31, 2022 | 99.42% |
| Dec 31, 2021 | 57.23% |
| Sep 30, 2021 | 100.60% |